BACKGROUND: Acute lower respiratory tract infections (ALRTI) are a leading cause of childhood mortality, but there are few data on disease costs in developing countries. OBJECTIVES: This study's purpose was to analyse ALRTI's costs-of-illness and economic burden in urban South African children. METHODS: ALRTI costs-of-illness (expressed in US$ 2010) at a tertiary hospital were measured using a micro-costing approach nested within a clinical trial. Demographic, epidemiological and data on use of health resources were integrated with costs-of-illness to estimate the economic burden of ALRTI in urban South African children aged <5 years. RESULTS:745 children experiencing 858 ALRTI episodes were studied. 338 (39.4%), 513 (59.8%) and 7 (0.8%) episodes were managed in short-stay, paediatric ward and intensive care settings, respectively. Mean lengths of stay in short-stay, paediatric ward and intensive care (ICU) were 1.4, 8.1 and 14.4 days, respectively. The societal costs-of-illness per ALRTI episode managed in short-stay and paediatric ward settings, respectively, were US$266 (95% CI 245-286) and 1287 (95% CI 1174-1401) in HIV-infected patients, and US$257 (95% CI 247-267) and 1032 (95% CI 931-1133) in HIV-uninfected patients. Family costs were not collected in ICUs. ICU direct medical costs were US$5968 (95% CI 4025-8056) in HIV-uninfected patients and US$7849 in one HIV-infected patient. Under-5 children experienced an estimated 424,220 episodes annually of ALRTI. ALRTI treatment cost the public health system an estimated US$28,975,000 while an additional US$539,000 of costs were borne by families. CONCLUSION: ALRTIs in children <5 years impose a heavy economic burden on families and the South African public health-care system.
RCT Entities:
BACKGROUND: Acute lower respiratory tract infections (ALRTI) are a leading cause of childhood mortality, but there are few data on disease costs in developing countries. OBJECTIVES: This study's purpose was to analyse ALRTI's costs-of-illness and economic burden in urban South African children. METHODS: ALRTI costs-of-illness (expressed in US$ 2010) at a tertiary hospital were measured using a micro-costing approach nested within a clinical trial. Demographic, epidemiological and data on use of health resources were integrated with costs-of-illness to estimate the economic burden of ALRTI in urban South African children aged <5 years. RESULTS: 745 children experiencing 858 ALRTI episodes were studied. 338 (39.4%), 513 (59.8%) and 7 (0.8%) episodes were managed in short-stay, paediatric ward and intensive care settings, respectively. Mean lengths of stay in short-stay, paediatric ward and intensive care (ICU) were 1.4, 8.1 and 14.4 days, respectively. The societal costs-of-illness per ALRTI episode managed in short-stay and paediatric ward settings, respectively, were US$266 (95% CI 245-286) and 1287 (95% CI 1174-1401) in HIV-infectedpatients, and US$257 (95% CI 247-267) and 1032 (95% CI 931-1133) in HIV-uninfectedpatients. Family costs were not collected in ICUs. ICU direct medical costs were US$5968 (95% CI 4025-8056) in HIV-uninfectedpatients and US$7849 in one HIV-infectedpatient. Under-5 children experienced an estimated 424,220 episodes annually of ALRTI. ALRTI treatment cost the public health system an estimated US$28,975,000 while an additional US$539,000 of costs were borne by families. CONCLUSION: ALRTIs in children <5 years impose a heavy economic burden on families and the South African public health-care system.
Authors: Matthew Biggerstaff; Cheryl Cohen; Carrie Reed; Stefano Tempia; Meredith L McMorrow; Sibongile Walaza; Jocelyn Moyes; Florette K Treurnicht; Adam L Cohen; Paul Hutchinson; Charles Stoecker; Joni Steinberg Journal: Vaccine Date: 2019-09-28 Impact factor: 3.641
Authors: Shanshan Zhang; Peter M Sammon; Isobel King; Ana Lucia Andrade; Cristiana M Toscano; Sheila N Araujo; Anushua Sinha; Shabir A Madhi; Gulam Khandaker; Jiehui Kevin Yin; Robert Booy; Tanvir M Huda; Qazi S Rahman; Shams El Arifeen; Angela Gentile; Norberto Giglio; Mejbah U Bhuiyan; Katharine Sturm-Ramirez; Bradford D Gessner; Mardiati Nadjib; Phyllis J Carosone-Link; Eric Af Simões; Jason A Child; Imran Ahmed; Zulfiqar A Bhutta; Sajid B Soofi; Rumana J Khan; Harry Campbell; Harish Nair Journal: J Glob Health Date: 2016-06 Impact factor: 4.413
Authors: Louise B Russell; Sri Ram Pentakota; Cristiana Maria Toscano; Ben Cosgriff; Anushua Sinha Journal: Clin Infect Dis Date: 2016-12-01 Impact factor: 9.079
Authors: Louise B Russell; Sun-Young Kim; Ben Cosgriff; Sri Ram Pentakota; Stephanie J Schrag; Ajoke Sobanjo-Ter Meulen; Jennifer R Verani; Anushua Sinha Journal: Vaccine Date: 2017-11-10 Impact factor: 3.641